Plain-English translation of NCT06728787 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether a robotic walking device called Lokomat, combined with standard physical therapy, can help people with hereditary spastic paraplegia (HSP) walk better and improve their daily functioning. HSP is a rare genetic condition that causes progressive stiffness and weakness in the legs. The study will measure changes in walking patterns, physical abilities, and overall quality of life.
Currently, there is no cure for hereditary spastic paraplegia, so treatment focuses on managing symptoms and slowing decline. This trial aims to determine whether robotic-assisted walking therapy could be an effective way to help people maintain and improve their walking ability and independence.
You likely qualify if…
You likely don't qualify if…
You would attend an intensive 3-week program involving 30 total sessions: 15 sessions using the Lokomat robotic walking device and 15 sessions of traditional physical therapy. Before starting, at the end of the 3 weeks, and again 3 months later, you would have your walking ability assessed using special movement analysis tools and standard physical tests. The study evaluates whether the improvements you make during treatment last over time.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
Italy